Nebivololo Sandoz (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivololo Sandoz, is a beta blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension and heart failure in adult patients. Nebivololo Sandoz is supplied as a prescription‑only product and is marketed in the European Union.

GNH USA supplies Nebivolo Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol acts on the cardiovascular system to lower blood pressure and improve cardiac output, making it useful in several related conditions.

Hypertension: Reduces systolic and diastolic blood pressure, helping to prevent stroke and myocardial infarction. Heart failure: Improves left‑ventricular ejection fraction and reduces symptoms of congestion, supporting long‑term disease management.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Dizziness or light‑headedness, especially on standing. - Fatigue or reduced exercise tolerance. - Bradycardia: heart rate below normal range. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to syncope. - Bronchospasm in patients with underlying airway disease. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Worsening heart failure symptoms, including pulmonary edema.

Nebivolol should be used with clinical vigilance and appropriate monitoring.

Monitor blood pressure: ensure target values are achieved without excessive drop. Assess heart rate: watch for bradycardia, especially in patients on other rate‑lowering agents. Use caution in asthma or COPD: β1‑selectivity reduces risk but bronchospasm can still occur. Review renal and hepatic function: dose adjustment may be needed in impairment. Avoid abrupt discontinuation: tapering reduces risk of rebound hypertension. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Other β‑blockers: additive negative chronotropic effects. - Non‑dihydropyridine calcium‑channel blockers (e.g., verapamil, diltiazem): may cause severe bradycardia or AV block. - Clonidine: concurrent use can lead to marked hypotension. - Anti‑arrhythmic agents (e.g., amiodarone): increased risk of conduction disturbances.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive response. - Diuretics: can potentiate hypotensive effect, monitor electrolytes. - Antidiabetic drugs: enhanced hypoglycaemia risk, observe glucose levels. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise nebivolol plasma concentrations. - ACE inhibitors or ARBs: monitor for additive blood‑pressure lowering.